PGY2 PROGRAM
Cardiology

Residency Program Director

  • Man in a white medical coat smiles while standing indoors near a window.

    Mike Boyd, PharmD, BCCP, BCPS

    • PGY2 Cardiology Residency Program Director, The Ohio State University Wexner Medical Center
    • Specialty Practice Pharmacist, Cardiology/Electrophysiology
    • Residency: Adult Medicine, St. Louis College of Pharmacy
    • PharmD: University of Cincinnati College of Pharmacy
    Contact

Recent Program Graduates

  • 2025

    Liz Mann, PharmD

    Inpatient Clinical Pharmacist, Evening Cardiology The University of Kansas Health System, Kansas City, KS
  • Marisol Wences, PharmD

    Cardiology Clinical Inpatient Specialist, University of Chicago Medicine, Chicago, IL
  • 2024

    Laura Andino, PharmD

    General Cardiology Clinical Pharmacy Specialist-Beth Israel Deaconess Medical Center-Boston , MA
  • Kyndol Craver, PharmD

    Cardiology Clinical Pharmacy Specialist-UT Southwestern-Dallas, TX

About the PGY2 Cardiology Residency Program

Purpose

PGY2 residency programs build upon Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency training to develop pharmacist practitioners with knowledge, skills, and abilities as defined in the educational competency areas, goals, and objectives for advanced practice areas. Residents who successfully complete PGY2 residency programs are prepared for advanced patient care or other specialized positions, and board certification in the advanced practice area, if available.

This residency is designed to enable the resident to gain comprehensive experience in managing patients with complicated cardiovascular disease states. Preceptors foster independence, critical thinking, and problem-solving skills in each resident. Residents gain valuable experience in direct patient care, research, literature evaluation, and committee involvement including leadership roles. In addition, residents will have ample opportunity to be involved in professional and academic teaching activities.

Residency Sites

Exterior view of a modern hospital building with glass and brick architecture.As one of America’s top ranked academic medical centers, the mission of The Ohio State University Wexner Medical Center (OSUWMC) is to improve people’s lives through innovation in research, education, and patient care. OSUWMC is a 1,506 bed multi-hospital delivery system recognized in 2024 as one of “America’s Best Hospitals” for excellence in ten specialties by US News and World Report based on quality, outcomes, and reputation.

The Ross Heart Hospital

The Richard M. Ross Heart Hospital at The OSUWMC is a 150-bed, comprehensive, cardiovascular center which specializes in the multidisciplinary care of patients in areas of  cardiovascular surgery, heart failure, pulmonary hypertension, heart and lung transplant , acute coronary syndromes, mechanical circulatory support  and electrophysiology. Each floor is dedicated to a specific service and combines the latest technology with patient –focused care to create the best possible healing environment. Our staff manages patients across a versatile spectrum of care, extending from critical care to the ambulatory setting.  Ohio State’s Heart and Vascular Center is considered one of the nation’s best hospitals for cardiology and heart surgery, as ranked by U.S. News & World Report, the only central Ohio hospital to earn a spot on the list. Our philosophy strongly supports working as a team to provide the right care to the right patient at the right time, in a safe and secure environment.

KEY ROTATIONS/EXPERIENCES

At OSUWMC, the resident will be responsible for participation in clinical pharmacy rounding services witGroup of people in white lab coats discuss in a medical or laboratory setting.h direct patient care responsibilities in a variety of settings. Most of the services are teaching services and may be composed of an attending physician, a fellow, and house staff (including residents, interns, and advanced practice providers). The resident will strengthen his/her clinical acumen and communication skills through completing at least one rotation on each required service. The remaining rotations will be determined based on the resident’s goals and the discretion of the residency program director.

Required Learning Experiences (4-5 weeks in duration unless noted otherwise):

  • General Cardiology
  • Acute Coronary Syndromes/Coronary Intensive Care
  • Heart Failure/Heart Transplant
  • Cardiovascular Intensive Care Unit
  • Thoracic Transplant
  • Electrophysiology (2 weeks)

Required Longitudinal Experiences:

  • Professional Education (including journal clubs and formal presentations)
  • Cardiology Committee Management
  • Research
  • Staffing

Sample Elective Learning Experiences (2-5 weeks in duration):

  • Cardiovascular Ambulatory Care
  • Neurocritical Care
  • Advanced rotation in any of the required learning experiences
  • Emergency Medicine
  • Pulmonary Hypertension

Key Preceptors

Danielle Blais, PharmD, BCCP, BCPS, FCCP
Acute Coronary Syndrome/Coronary Intensive Care

Mike Boyd, PharmD, BCCP, BCPS
Electrophysiology/ Cardiology

Pam Burcham, PharmD, BCTXP, BCPS
Thoracic Transplant

Shea Macielak, PharmD, BCCP
Cardiovascular Float

Tara Fallah, PharmD, BCTXP
Thoracic Transplant

Kevin Kissling, PharmD, BCPS
Heart Failure/Heart Transplant

Kerry Pickworth, PharmD, FCCP
Heart Failure/Heart Transplant

Alan Rozycki, PharmD, BCCCP
Cardiovascular Intensive Care Unit

Selected Resident Research

  • Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery. J Card Surg. 2022 Dec; 37(12):4740-4747. Naik KD, Whitson BA, McLaughlin EM, Matre NB, Rozycki AJ.
  • Rehospitalization of patients with advanced heart failure receiving continuous, palliative dobutamine or milrinone. Am J Cardiol. 2022 Dec 1;184:80-89. Eaton RE, Kissling KT, Haas GJ, McLaughlin EM, Pickworth KK.
  • Risk factors and outcomes associated with prolonged subtherapeutic anticoagulation with bivalirudin: A retrospective cohort study. Pharmacotherapy. 2019 Dec;39(12):1157-1166. Orzel LA, Abel EE, Blais DM, Wang TF, Porter KA, Burcham PK.
  • Impact of anticoagulation strategy and agents on extracorporeal membrane oxygenation therapy. Perfusion. 2019 Nov;34(8):671-678. Macielak S, Burcham P, Whitson B, Abdel-Rasoul M, Rozycki A.
  • Outcomes for cancer patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiovasc Revasc Med. 2019 Aug;20(8):711-715. Jacobs JA, Pickworth K, Boudoulas KD, Hinkley M, McLaughlin E, Blais D.
  • Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin. Clin Transplant. 2018 Nov;32(11):e13420. Jewani PK, Pouch SM, Kissling KT.
  • Comparison of the safety of adenosine and regadenoson in patients undergoing outpatient cardiac stress testing. Pharmacotherapy. 2015 Dec;35(12):1117-23. Brink HL, Dickerson JA, Stephens JA, Pickworth KK.

Benefits and Additional Requirements

Application Deadline:
January 4

We welcome applications from non-U.S. citizens who have a “green card” (permanent resident status) or a current visa valid through the entire duration of the residency program. The Ohio State University pharmacy residency programs are NOT able to sponsor visas for pharmacy residents (PGY1 or PGY2).

Start Date: July 1

Annual Salary – $56,000

Vacation Days – 10 days

Staffing Requirement – 19 weekends a year

Completion of a Major Research Project

Four people in white lab coats carry laptops & walk down a hallway.

TEACHING OPPORTUNITIES

Download PDF